# Generalized Morphea Successfully Treated With Tripterygium Glycosides and Hydroxychloroquine: A Case Report and a Systematic Review

**Authors:** Zufeng Sun, Jingjing Chen, Xiulian Xu, Jiahui Zhang, Xu Yao

PMC · DOI: 10.7759/cureus.102597 · Cureus · 2026-01-29

## TL;DR

A 61-year-old man with generalized morphea was successfully treated with tripterygium glycosides and hydroxychloroquine, suggesting a new potential treatment approach.

## Contribution

The paper introduces a novel combination therapy of tripterygium glycosides and hydroxychloroquine for generalized morphea.

## Key findings

- The combination of tripterygium glycosides and hydroxychloroquine successfully treated a case of generalized morphea.
- Systemic glucocorticoid is currently the most frequently used and effective treatment for generalized morphea.
- Pediatric patients showed higher rates of abnormal antinuclear antibodies and more severe cases compared to adults.

## Abstract

Generalized morphea, a rare and severe variant of localized scleroderma, is marked by extensive skin involvement with multiple hardened plaques and hyperpigmentation. The pathogenesis of generalized morphea is still unclear, and there is no established therapy. The aim of this article is to present a novel treatment approach for generalized morphea while also conducting a systematic review of previously published cases to summarize and analyze the clinical features and current effective treatment strategies for this condition. We herein describe the case of a 61-year-old male patient with generalized morphea successfully treated with tripterygium glycosides (TG) and hydroxychloroquine (HCQ). The systematic review analyzed a total of 77 patients with generalized morphea, comprising 76 previously reported cases (57 adults and 19 children) and one adult patient from our article. Compared with the adult group, the pediatric group demonstrated significantly higher rates of abnormal antinuclear antibodies (78.9%, p=0.002) and a greater proportion of severe cases (89.5%, p=0.001). Furthermore, systemic glucocorticoid is currently the most frequently used and effective treatment (p=0.016). In the treatment of generalized morphea, the combination of HCQ and TG may represent a potentially useful therapeutic option worthy of further investigation.

## Linked entities

- **Chemicals:** hydroxychloroquine (PubChem CID 3652)
- **Diseases:** scleroderma (MONDO:0005100)

## Full-text entities

- **Genes:** LSM2 (LSM2 homolog, U6 small nuclear RNA and mRNA degradation associated) [NCBI Gene 57819] {aka C6orf28, G7B, YBL026W, snRNP}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, CRP (C-reactive protein) [NCBI Gene 1401] {aka PTX1}
- **Diseases:** systemic sclerosis (MESH:D012595), systemic lupus erythematosus (MESH:D008180), itching (MESH:D011537), erythema (MESH:D004890), eosinophilic fasciitis (MESH:C562487), primary biliary cholangitis (MESH:D008105), Raynaud phenomenon (MESH:D011928), skin induration (MESH:D010411), autoimmune diseases (MESH:D001327), sclerosis (MESH:D012598), atrophy (MESH:D001284), polymyositis (MESH:D017285), joint pain (MESH:D018771), pigmentation (MESH:D010859), immunological abnormalities (MESH:D007154), Morphea (MESH:D012594), erythematous plaques (MESH:D003773), Sjogren's syndrome (MESH:D012859), sclerodactyly (MESH:C535336), leg length discrepancy (MESH:D007870), skin ulcers (MESH:D012883), infection (MESH:D007239), restricted joint mobility (MESH:D014086), hyperpigmentation (MESH:D017495), skin disorder (MESH:D012871), hypertension (MESH:D006973), pain (MESH:D010146), systemic autoimmune syndrome (MESH:D020274), rheumatoid arthritis (MESH:D001172), dysphagia (MESH:D003680), trauma (MESH:D014947), inflammatory (MESH:D007249)
- **Chemicals:** CTX (MESH:D003520), calcitriol (MESH:D002117), imatinib (MESH:D000068877), MTX (MESH:D008727), AZA (MESH:D001379), psoralen (MESH:D005363), ciclosporin (MESH:D016572), HCQ (MESH:D006886), H&amp;E (MESH:D006371), TG (-), MMF (MESH:D009173)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12949718/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12949718/full.md

## References

10 references — full list in the complete paper: https://tomesphere.com/paper/PMC12949718/full.md

---
Source: https://tomesphere.com/paper/PMC12949718